SAN CARLOS, Calif.--(BUSINESS WIRE)--Simpirica Spine Inc. developer of minimally invasive, flexion-restricting stabilization devices for the spine, has announced U.S. Food and Drug Administration (FDA) approval to begin an investigational device exemption (IDE) pivotal clinical study of its LimiFlex Spinal Stabilization System. The LimiFlex is a novel dynamic stabilization system designed to address flexion (forward bending) pain and instability without the need for spinal fusion.
